https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54297 Wed 28 Feb 2024 15:52:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51366 Wed 28 Feb 2024 15:46:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53799 Wed 28 Feb 2024 15:24:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45252 Wed 26 Oct 2022 17:55:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45003 n = 19), including 7 with NEA and healthy controls (n = 10) underwent a clinical assessment, venepuncture and sputum induction. MDMs were co-cultured with apoptotic granulocytes isolated from healthy donors with or without exogenous recombinant galectin-3 (50 μg/mL) and efferocytosis was assessed by flow cytometry. Galectin-3 expression and localisation in MDMs was visualised by immunofluorescence staining and fluorescence microscopy. Galectin-3, interleukin (IL)-6 and CXCL8 secretion were measured in cell culture supernatants by ELISA and cytometric bead array. Results: Baseline efferocytosis (mean (±standard deviation)) was lower in participants with asthma (33.2 (±17.7)%) compared with healthy controls (45.3 (±15.9)%; p = 0.081). Efferocytosis did not differ between the participants with eosinophilic asthma (EA) (31.4 (±19.2)%) and NEA (28.7 (±21.5)%; p = 0.748). Addition of galectin-3 significantly improved efferocytosis in asthma, particularly in NEA (37.8 (±18.1)%) compared with baseline (30.4 (±19.7)%; p = 0.012). Efferocytosis was not associated with any of the clinical outcomes but was negatively correlated with sputum macrophage numbers (Spearman r = − 0.671; p = 0.017). Galectin-3 was diffusely distributed in most MDMs but formed punctate structures in 5% of MDMs. MDM galectin-3 secretion was lower in asthma (9.99 (2.67, 15.48) ng/mL) compared with the healthy controls (20.72 (11.28, 27.89) ng/mL; p = 0.044) while IL-6 and CXCL8 levels were similar. Conclusions: Galectin-3 modulates macrophage function in asthma, indicating a potential role for galectin-3 to reverse impaired efferocytosis in NEA.]]> Wed 26 Oct 2022 09:42:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22109 Wed 25 Sep 2024 08:44:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32080 Wed 24 Nov 2021 15:52:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32651 30 kg/m²). Exacerbations requiring medical intervention were recorded prospectively. Asthma control, medication use, and fractional exhaled nitric oxide were assessed monthly; additional visits occurred during exacerbations. Peripheral blood was collected at baseline for the measurement of eosinophils, soluble CD-163, C-reactive protein, and IL-6. Results: Exacerbations occurred in a higher proportion of overweight (51.1%) and obese (48.4%) women compared with healthy weight women (25%; P =.026). Excess weight gain during pregnancy was not associated with exacerbation risk. Macrophage activation (elevated serum soluble CD-163) was associated with exacerbations requiring oral corticosteroids (P =.043), whereas high peripheral blood eosinophils or fractional exhaled nitric oxide were not associated with exacerbation or oral corticosteroid use. Conclusions: Being overweight or obese confers a greater risk of asthma exacerbation during pregnancy, and may be due to systemic macrophage activation.]]> Wed 19 Jan 2022 15:19:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31003 Wed 19 Jan 2022 15:18:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13797 Wed 18 Sep 2024 14:21:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14146 Wed 14 Aug 2024 09:09:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46073 Wed 13 Mar 2024 13:53:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15253 Wed 11 Apr 2018 17:15:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22041 Wed 11 Apr 2018 16:59:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2764 Wed 11 Apr 2018 16:29:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12524 Wed 11 Apr 2018 15:30:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10307 Wed 11 Apr 2018 15:17:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15377 Wed 11 Apr 2018 13:30:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22224 Wed 11 Apr 2018 13:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28242 Wed 11 Apr 2018 12:02:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:11811 Wed 11 Apr 2018 11:55:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:17382 Wed 11 Apr 2018 11:02:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19199 Wed 11 Apr 2018 10:44:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22540 Wed 11 Apr 2018 10:17:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36433 + neutrophils as median fluorescence intensity (MFI). Results: Neutrophil surface expression of CD62L was significantly reduced in COPD (median (IQR) MFI: 1156 (904, 1365)) compared with asthma (1865 (1157, 2408)) and healthy controls (2079 (1054, 2960)); p=0.028. COPD neutrophils also demonstrated a significant reduction in CD62L expression with and without fMLF stimulation. Asthma participants had a significantly increased proportion and number of CD62L^bright/CD16^dim neutrophils (median: 5.4% and 0.14 x 10⁹/L, respectively), in comparison with healthy (3.54% and 0.12 x 10⁹/L, respectively); p<0.017. Conclusion: Reduced CD62L expression suggests blood neutrophils have undergone priming in COPD but not in asthma, which may be the result of systemic inflammation. The increased shedding of CD62L receptor by COPD blood neutrophils suggests a high sensitivity for activation]]> Wed 10 Nov 2021 15:05:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32663 Wed 10 Nov 2021 15:04:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49859 Wed 07 Jun 2023 10:25:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52880 Tue 31 Oct 2023 10:44:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44917 P <0.001). In conclusion, the consumption of fast foods, particularly hamburgers, correlates to asthma in a dose-response pattern, which needs to be further validated in longitudinal and interventional studies.]]> Tue 25 Oct 2022 09:17:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:56413 Tue 17 Sep 2024 15:07:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:56417 Tue 17 Sep 2024 15:07:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:56408 Tue 17 Sep 2024 14:52:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:11837 Tue 17 Sep 2024 09:43:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45225 Thu 27 Oct 2022 15:10:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45336 Thu 27 Oct 2022 10:50:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:29462 IRAKM, PCDH1, ORMDL3/GSDMB, IL-33, CDHR3 and CST1 in airway epithelial cells. Recent studies on epigenetic regulatory factors have further provided novel insights to the field, particularly their effect on regulation of some of the asthma susceptibility genes (e.g. methylation of ADAM33). Among the epigenetic regulatory mechanisms, microRNA networks have been shown to regulate a major portion of post-transcriptional gene regulation. Particularly, miR-19a may have some therapeutic potential.]]> Thu 24 Mar 2022 11:32:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53382 Thu 23 Nov 2023 12:54:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48967 Thu 20 Apr 2023 10:09:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31150 Thu 17 Feb 2022 09:28:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:33763 Thu 17 Feb 2022 09:27:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8221 Thu 11 Jul 2019 11:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:30829 Thu 09 Dec 2021 11:04:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:34690 Thu 03 Feb 2022 12:20:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8465 Sat 24 Mar 2018 08:42:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8406 Sat 24 Mar 2018 08:40:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7384 Sat 24 Mar 2018 08:40:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8459 Sat 24 Mar 2018 08:38:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8668 Sat 24 Mar 2018 08:38:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8664 Sat 24 Mar 2018 08:38:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7533 Sat 24 Mar 2018 08:38:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8198 Sat 24 Mar 2018 08:36:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1373 Sat 24 Mar 2018 08:28:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2984 1 week) supplementation trials have been promising. However, the development of techniques to study isoprostanes in airway­lining fluid pave the way for further studies investigating the potential for antioxidant supplements to be used as routine therapy in asthma.]]> Sat 24 Mar 2018 08:27:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14580 Sat 24 Mar 2018 08:22:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:15235 H2 cytokine production, and airway hyperresponsiveness. The anti-inflammatory effects of miR-145 antagonism were comparable to steroid treatment. Conclusion: Our study highlights the importance of understanding the contribution of miRNAs to pathogenesis of human allergic disease and their potential as novel anti-inflammatory targets.]]> Sat 24 Mar 2018 08:21:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14509 Sat 24 Mar 2018 08:19:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16017 Sat 24 Mar 2018 08:19:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13283 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13284 Sat 24 Mar 2018 08:15:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16923 Sat 24 Mar 2018 08:00:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18462 3% and > 61% respectively. Peripheral blood monocytes were isolated (n = 61) and sputum macrophages were isolated from a subgroup of patients with asthma (n = 14), using immunomagnetic cell separation. RNA and nuclear proteins were extracted and quantified. Enzyme activity was assessed using fluorescent assays and gene expression of EP300, KAT2B, CREBBP, and HDACs 1, 2 and 3 were measured by qPCR. Results: There was a significant inverse association between blood monocyte HAT and HDAC activity (r = −0.58, P < 0.001). NA was associated with increased blood monocyte HAT enzyme activity (P = 0.02), decreased HDAC activity (P = 0.03), and increased HAT: HDAC ratio (P < 0.01) compared with eosinophilic asthma. There were no differences in gene expression of EP300, KAT2B, CREBBP, or HDACs 1, 2 and 3 in blood monocytes from subjects with asthma or inflammatory phenotypes of asthma. There was no effect of inhaled corticosteroid use, poor asthma control, or asthma severity on HAT/HDAC activities. Sputum macrophages had increased expression of KAT2B in eosinophilic compared with paucigranulocytic asthma. Conclusions and Clinical Relevance: Neutrophilic airway inflammation is associated with increased HAT and reduced HDAC activity in blood monocytes, demonstrating further systemic manifestations relating to the altered inflammatory gene transcription profile of neutrophilic asthma.]]> Sat 24 Mar 2018 07:59:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18979 Sat 24 Mar 2018 07:58:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20875 Sat 24 Mar 2018 07:57:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:20580 Sat 24 Mar 2018 07:55:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19229 9/L. The blood eosinophil/lymphocyte ratio (ELR) and eosinophil/neutrophil ratio (ENR) were increased in eosinophilic asthma, and the neutrophil/lymphocyte ratio (NLR) was increased in neutrophilic asthma. Neutrophilic asthma could also be detected by blood neutrophil percentages and NLR, but with less accuracy. Conclusions and Clinical Relevance: Blood eosinophil counts and derived ratios (ELR and ENR) can accurately predict eosinophilic asthma in patients with persistent uncontrolled asthma despite treatment. Blood neutrophil parameters are poor surrogates for the proportion of sputum neutrophils. Blood counts may be a useful aid in the monitoring of uncontrolled asthma.]]> Sat 24 Mar 2018 07:54:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18331 Sat 24 Mar 2018 07:52:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5604 Sat 24 Mar 2018 07:49:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5103 Sat 24 Mar 2018 07:48:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:6787 Sat 24 Mar 2018 07:46:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:100 Sat 24 Mar 2018 07:42:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27857 Sat 24 Mar 2018 07:41:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:29168 n = 7) or non-allergic (control, n = 5), and subjected to repeated airway challenges with HDM (allergic group) or saline (control group) throughout gestation. Maternal lung, fetal and placental phenotypes were characterised at 140 ± 1 days gestational age (term, ~147 days). The eosinophil influx into lungs was greater after HDM challenge in allergic ewes than after saline challenge in control ewes before mating and in late gestation. Airway resistance increased throughout pregnancy in allergic but not control ewes, consistent with increased airway smooth muscle in allergic ewes. Maternal allergic asthma decreased relative fetal weight (-12%) and altered placental phenotype to a more mature form. Expression of surfactant protein B mRNA was 48% lower in fetuses from allergic ewes than controls, with a similar trend for surfactant protein D. Thus, allergic asthma in pregnant sheep modifies placental phenotype, and inhibits fetal growth and lung development consistent with observations from human pregnancies. Preconceptional allergen sensitisation and repeated airway challenges in pregnant sheep therefore provides an animal model to identify mechanisms of altered fetal development and adverse pregnancy outcomes caused by maternal asthma in pregnancy.]]> Sat 24 Mar 2018 07:35:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27821 Sat 24 Mar 2018 07:31:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:4818 Sat 24 Mar 2018 07:18:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22281 Sat 24 Mar 2018 07:17:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22049 Sat 24 Mar 2018 07:15:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:25197 Sat 24 Mar 2018 07:14:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22105 Sat 24 Mar 2018 07:10:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38982 Mon 29 Jan 2024 17:51:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38659 Mon 29 Jan 2024 17:49:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47276 Mon 27 Mar 2023 13:58:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12423 Mon 26 Aug 2024 12:36:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:2879 Mon 23 Sep 2019 14:24:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:32745 Mon 23 Sep 2019 14:10:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:34885 Mon 23 Sep 2019 11:28:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47479 Mon 23 Jan 2023 11:40:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1059 Mon 16 Sep 2024 13:54:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37007 ENO and symptoms (F_ENO group). Exacerbations were recorded prospectively. Height and weight were measured at baseline, and in late pregnancy. GWG was categorized according to Institute of Medicine guidelines. A validated parent-completed questionnaire assessed infant wheeze-related outcomes. Results: F_ENO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104). Recurrent bronchiolitis occurred in 5.3% (n = 1) of infants born to non-overweight mothers, 16.7% (n = 3) of infants of overweight mothers, and 21.7% (n = 5) of infants of obese mothers in the control group. In the F_ENO group, 2 infants of obese mothers had recurrent bronchiolitis (7.1%, P = .031). Conclusions: The benefits of F_ENO-based management are attenuated among obese mothers and those with excess GWG, indicating the importance of weight management in contributing to improved asthma management in pregnancy.]]> Mon 14 Nov 2022 20:28:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46232 Mon 14 Nov 2022 12:33:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55396 Fri 24 May 2024 10:54:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:23240 Fri 22 Apr 2022 10:21:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:26397 1.5 at randomization and ≤1.5 at end of study) and unimproved (ACQ7>1.5 at end of study). Regression models were fitted for each psychosocial measure at the end of the study, with adjustment for baseline values and smoking status, with predictor variable asthma control. Results: Women with unimproved asthma had poorer physical (SF12, p=0.012) and asthma-specific quality of life across all domains (AQLQ-M, p≤0.012) compared to women with controlled asthma. They believed that they had less control over their asthma (PCAQ total p=0.014), had more symptoms and that their illness had a greater effect on their emotions and their lives in general (BIPQ identity, consequences, concern, emotional response p≤0.015). Women with improved asthma control had significantly lower AQLQ-M breathlessness (p=0.048) and lower total scores (p=0.04) than women with controlled asthma. Conclusions: Pregnant women who are not able to get control of their asthma symptoms may experience worse quality of life and are likely to have more negative perceptions about their condition.]]> Fri 13 Sep 2024 14:33:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46047 Fri 11 Nov 2022 14:11:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46080 Fri 11 Nov 2022 10:10:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45534 Fri 04 Nov 2022 14:45:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45561 Fri 04 Nov 2022 14:44:44 AEDT ]]>